CER Daily Newsfeed

John O'Brien: Drug-Level Insights about Development Pathways for Cancer Treatments

(10/23, OncoDaily) reports “John O'Brien, President and CEO of the National Pharmaceutical Council, shared a post on LinkedIn...‘New research from the National Pharmaceutical Council published in Therapeutic Innovation and Regulatory Science provides drug-level insights about development pathways for Cancer Treatments and the potential impact of the IRA's Medicare Drug Price Negotiation Program. This cross-sectional study evaluated 86 oncology drugs first approved by the FDA from 2008 to 2018 — 56 (65.1%) of which were later approved for one or more additional indications. The research is unique because it captures drug-level trajectories toward subsequent indications.’” Full

Early Use of Triple Oral Therapy May Lower Hospitalizations for PAH

(10/23, The American Journal of Managed Care) reports “...The insight comes from a comparative effectiveness study, which found that the addition of selexipag (Uptravi) to double oral therapy (DOT) with an endothelin receptor antagonist (ERA) and a phosphodiesterase type 5 inhibitor (PDE5i) reduced the hospitalization risk for patients with PAH and the risk of their disease progressing.” Full

Health Care Leaders Push Forward on Value-Based Care Amid Challenges

(10/23, Hayden E. Klein, The American Journal of Managed Care) reports “...Value-based care prioritizes patient outcomes and cost reduction, requiring alignment of reimbursement models and financial sustainability management. Private insurers are reforming payment models, but aligning specialty care with value-based goals remains challenging.” Full

UK: NICE Recommendation for New Alexion PNH Treatment

(1024, John Pinching, PharmaTimes) reports “Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral Factor D inhibitor can now be used as an add-on to ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with residual haemolytic anaemia, provided they have clinically significant extravascular haemolysis (EVH) while on treatment with a complement component 5 inhibitor (C5 inhibitor).” Full